Related Experiment Video
Updated: Jun 19, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Valsartan: the past, present and future
Lars Køber1, Christian Torp-Pedersen
1Rigshospitalet-Copenhagen University Hospital, Department of Cardiology, The Heart Centre, Non-Invasive Lab, 9 Blegdamsvej, Copenhagen, Denmark 2100. lk@heart.dk
Abstract:
Valsartan (Diovan) is a widely use angiotensin receptor blocker that prevents angiotensin II from binding to the subtype 1 receptor. Stimulation of the subtype 1 receptor is believed to mediate many of the deleterious effects accompanied by increased angiotensin II levels. Valsartan is effective in the treatment of hypertension, alone and in combination with hydrochlorothiazide. Valsartan is similarly as effective as angiotensin-converting enzyme (ACE) blockers following myocardial infarction accompanied with left ventricular dysfunction, and/or heart failure. For the treatment of congestive heart failure with left ventricular dysfunction, valsartan offers a reduction in mortality in patients not able to tolerate an ACE inhibitor and in combination with an ACE inhibitor, valsartan reduces morbidity (hospitalization for heart failure).
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Aortic Regurgitation III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Dose-Response Relationship: Potency and Efficacy
Heart Failure V: Medical Management